HK1016594A1 - Eprosartan dihydrate and a process for its production and formulation - Google Patents

Eprosartan dihydrate and a process for its production and formulation

Info

Publication number
HK1016594A1
HK1016594A1 HK99101567A HK99101567A HK1016594A1 HK 1016594 A1 HK1016594 A1 HK 1016594A1 HK 99101567 A HK99101567 A HK 99101567A HK 99101567 A HK99101567 A HK 99101567A HK 1016594 A1 HK1016594 A1 HK 1016594A1
Authority
HK
Hong Kong
Prior art keywords
formulation
production
eprosartan
dihydrate
eprosartan dihydrate
Prior art date
Application number
HK99101567A
Other languages
English (en)
Inventor
Nageswara R Palepu
Gopadi M Venkatesh
Sarma Duddu
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21765344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1016594(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of HK1016594A1 publication Critical patent/HK1016594A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
HK99101567A 1996-03-29 1999-04-13 Eprosartan dihydrate and a process for its production and formulation HK1016594A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1441496P 1996-03-29 1996-03-29
PCT/US1997/004877 WO1997036874A1 (en) 1996-03-29 1997-03-26 Eprosartan dihydrate and a process for its production and formulation

Publications (1)

Publication Number Publication Date
HK1016594A1 true HK1016594A1 (en) 1999-11-05

Family

ID=21765344

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99101567A HK1016594A1 (en) 1996-03-29 1999-04-13 Eprosartan dihydrate and a process for its production and formulation

Country Status (36)

Country Link
EP (1) EP0889880B1 (ro)
JP (1) JP4316013B2 (ro)
CN (2) CN1214682A (ro)
AP (1) AP901A (ro)
AR (1) AR006439A1 (ro)
AT (1) ATE239723T1 (ro)
AU (1) AU726694B2 (ro)
BG (1) BG64095B1 (ro)
BR (1) BR9708336A (ro)
CA (1) CA2250395C (ro)
CZ (1) CZ293345B6 (ro)
DE (1) DE69721749T2 (ro)
DK (1) DK0889880T3 (ro)
DZ (1) DZ2199A1 (ro)
EA (1) EA001958B1 (ro)
EG (1) EG23889A (ro)
ES (1) ES2198564T3 (ro)
HK (1) HK1016594A1 (ro)
HU (1) HU228263B1 (ro)
ID (1) ID16507A (ro)
IL (1) IL126319A0 (ro)
MA (1) MA24437A1 (ro)
MY (1) MY117682A (ro)
NO (2) NO311760B1 (ro)
NZ (1) NZ332008A (ro)
OA (1) OA11176A (ro)
PL (1) PL188816B1 (ro)
PT (1) PT889880E (ro)
RO (1) RO118870B1 (ro)
SK (1) SK282346B6 (ro)
TR (1) TR199801954T2 (ro)
TW (1) TW434239B (ro)
UA (1) UA49880C2 (ro)
UY (1) UY24504A1 (ro)
WO (1) WO1997036874A1 (ro)
ZA (1) ZA972686B (ro)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262102B1 (en) * 1997-06-27 2001-07-17 Smithkline Beecham Corporation Eprosartan monohydrate
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
AU750611B2 (en) * 1997-11-17 2002-07-25 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
ID25640A (id) 1998-03-04 2000-10-19 Takeda Chemical Industries Ltd Preparat pelepasan terus menerus untuk antagonistik aii, produksi dan penggunaannya
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
WO2000004862A2 (en) * 1998-07-20 2000-02-03 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
GB9820405D0 (en) 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
AU1157500A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof
DK1197223T3 (da) * 1999-04-28 2005-05-30 Takeda Pharmaceutical Farmaceutisk præparat til forebyggelse, behandling eller udviklingsinhibition af simpel retinopati eller præproliferativ retinopati
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
CZ20023381A3 (cs) * 2000-04-12 2003-02-12 Novartis Ag Kombinované farmaceutické prostředky obsahující antagonistu AT1-receptoru nebo/a inhibitor HMG-CoA reduktázy nebo/a ACE inhibitor
AU2002364381A1 (en) * 2001-11-23 2003-06-10 Solvay Pharmaceuticals Gmbh Hypertonia treatment during the acute phase of a cerebrovascular accident
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
RU2004137109A (ru) * 2002-05-17 2005-10-10 Новартис АГ (CH) Комбинация блокатора рецептора ангиотензина ii и бетаблокатора для вторичной профилактики инфаркта миокарда
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP3045174A1 (en) 2003-01-31 2016-07-20 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
WO2009013760A2 (en) 2007-07-25 2009-01-29 Hetero Drugs Limited Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
WO2009084028A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd Improved process for manufacturing anhydrous (e)-3-[2-butyl-1- {(4-carboxyphenyl) methyl}-1h-imidazole-5-yl]-(thiophen-2- ylmethyl)prop-2-enoic acid methane sulfonate
CN101333216A (zh) 2008-08-03 2008-12-31 浙江华海药业股份有限公司 一种新的依普罗沙坦甲磺酸盐成盐工艺
CN113354553B (zh) * 2021-06-03 2023-09-15 北京宝诺康医药科技有限公司 一种甲氧氯普胺单盐酸盐一水合物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
AU9137791A (en) * 1990-12-14 1992-07-08 Smithkline Beecham Corporation Imidazolyl-alkenoic acids

Also Published As

Publication number Publication date
ZA972686B (en) 1997-09-29
HUP9902769A3 (en) 2000-04-28
EP0889880A4 (en) 1999-06-23
AU2547097A (en) 1997-10-22
EP0889880A1 (en) 1999-01-13
EG23889A (en) 2007-12-12
TR199801954T2 (xx) 1998-12-21
DE69721749T2 (de) 2004-03-25
PT889880E (pt) 2003-09-30
HU228263B1 (en) 2013-02-28
NZ332008A (en) 1999-05-28
IL126319A0 (en) 1999-05-09
HUP9902769A2 (hu) 2000-03-28
EA001958B1 (ru) 2001-10-22
MY117682A (en) 2004-07-31
UA49880C2 (uk) 2002-10-15
CA2250395C (en) 2005-09-06
CZ293345B6 (cs) 2004-04-14
SK282346B6 (sk) 2002-01-07
WO1997036874A1 (en) 1997-10-09
ES2198564T3 (es) 2004-02-01
AR006439A1 (es) 1999-08-25
AU726694B2 (en) 2000-11-16
BR9708336A (pt) 1999-08-03
OA11176A (en) 2003-05-13
JP2000508632A (ja) 2000-07-11
ID16507A (id) 1997-10-02
MA24437A1 (fr) 1998-10-01
EA199800873A1 (ru) 1999-02-25
BG102822A (en) 1999-11-30
DE69721749D1 (de) 2003-06-12
PL329046A1 (en) 1999-03-01
PL188816B1 (pl) 2005-04-29
RO118870B1 (ro) 2003-12-30
CN1332167A (zh) 2002-01-23
TW434239B (en) 2001-05-16
NO984503D0 (no) 1998-09-28
CZ310198A3 (cs) 1999-03-17
BG64095B1 (bg) 2003-12-31
DZ2199A1 (fr) 2002-12-03
NO311760B1 (no) 2002-01-21
EP0889880B1 (en) 2003-05-07
DK0889880T3 (da) 2003-09-01
NO984503L (no) 1998-09-28
AP9700956A0 (en) 1997-04-30
NO2002005I1 (no) 2002-09-02
SK132298A3 (en) 1999-03-12
CN1214682A (zh) 1999-04-21
ATE239723T1 (de) 2003-05-15
UY24504A1 (es) 1997-09-19
CA2250395A1 (en) 1997-10-09
JP4316013B2 (ja) 2009-08-19
AP901A (en) 2000-11-23

Similar Documents

Publication Publication Date Title
EG23889A (en) Eprosartan dihydrate and a process for its production and formulation
HUP0001949A3 (en) Refastenable packing and process for manufacturing refastenable packing
IL133195A0 (en) Nonsteroidal gestagen compounds and processes for their production
HUP9903454A3 (en) A crystalline form of cefditoren pivoxyl and process for the production of the same
HUP9603112A2 (en) New pharmaceutical formulation and process for its production
IL131298A0 (en) A pharmaceutical composition and a process for producing the same
EP1047407A4 (en) METHOD FOR PRODUCING A COUTINE TABLET
HUP0000066A3 (en) Olanzapine dihydrate and process for preparing olanzapine form ii
EP0941668A4 (en) SORBETS AND THEIR MANUFACTURING METHODS
IL125194A0 (en) Process for manufacturing felodipine
GB9605597D0 (en) Process for making confectionery
HK1031688A1 (en) Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation
GB9819651D0 (en) Matrerial and process for its production
HUP0104213A3 (en) Vancoresmycin, a process for its production and its use as a pharmaceutical
GB2317322B (en) A biscuit manufacturing process
SI0889880T1 (en) Eprosartan dihydrate and a process for its production and formulation
PL345192A1 (en) Mumbaistatin, a process for its production and its use as a pharmaceutical
GB9602805D0 (en) Production process
HU9701137D0 (en) Process for producing pharmaceutical intermedier
GB9709762D0 (en) Production process
SI1027047T1 (sl) Arginil kompleks eprosartana za nevtralizacijo naboja in postopek za njegovo izdelavo in formulacijo
GB9711802D0 (en) Process for confectionery production
GB9615770D0 (en) Production process
GB9604097D0 (en) Production process
HU9800144D0 (en) Artifically growed dripstone and process for production thereof

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20170325